Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences Apr 8, 2024 08:00AM
Sail Biomedicines Provides Update on Research with Cystic Fibrosis Foundation and Pioneering Medicines Jan 5, 2024 10:00AM
Flagship Pioneering Launches Pioneering Intelligence Nov 1, 2023 10:30AM
Invaio achieves first registration for citrus greening solution featuring Trecise™ technology Aug 29, 2023 09:00AM
Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of Biomimicry May 16, 2023 06:00AM


Apr 12, 2023 08:00AM Biogen Exercises Option with Denali to Develop and Commercialize Antibody Transport Vehicle Program Targeting Amyloid Beta
Apr 12, 2023 08:00AM Biogen Exercises Option with Denali to Develop and Commercialize Antibody Transport Vehicle Program Targeting Amyloid Beta
Oct 3, 2022 08:00AM Biogen and Denali Therapeutics Announce Initiation of the Phase 3 LIGHTHOUSE Study in Parkinson’s Disease Associated with LRRK2 Pathogenic Mutations
Oct 3, 2022 08:00AM Biogen and Denali Therapeutics Announce Initiation of the Phase 3 LIGHTHOUSE Study in Parkinson’s Disease Associated with LRRK2 Pathogenic Mutations
Aug 16, 2022 07:00AM Senda Biosciences Announces Close of $123 Million Series C Financing
May 31, 2022 08:04AM Denali Therapeutics (DNLI), Biogen (BIIB) Initiate Phase 2b Study of LRRK2 Inhibitor in Parkinson's Disease
May 31, 2022 08:00AM Denali Therapeutics and Biogen Announce Initiation of Phase 2b Study of LRRK2 Inhibitor in Parkinson’s Disease
May 31, 2022 08:00AM Denali Therapeutics and Biogen Announce Initiation of Phase 2b Study of LRRK2 Inhibitor in Parkinson’s Disease
Feb 15, 2022 10:05AM INVAIO SCIENCES STRENGTHENS ITS BOARD OF DIRECTORS WITH THE APPOINTMENT OF HUGH GRANT
Jan 26, 2022 09:31AM Senda Biosciences Appoints Stuart Milstein, Ph.D., as SVP and Head of Platform Biology
Oct 13, 2021 10:11AM Invaio Sciences Secures $50 Million Debt Financing to Develop and Commercialize Agricultural Solutions to Address Climate Change
Aug 30, 2021 06:30AM Laronde Attracts $440M in First External Financing to Further Advance Endless RNA™ Platform
Aug 6, 2020 08:09AM Biogen (BIIB), Denali (DNLI) to Collaborate on LRRK2 Program for Parkinson’s Disease and Certain TV Platform-Enabled Programs for Neurodegenerative Diseases
Aug 6, 2020 08:02AM Biogen and Denali to Collaborate on LRRK2 Program for Parkinson’s Disease and Certain TV Platform-Enabled Programs for Neurodegenerative Diseases
Aug 6, 2020 08:02AM Biogen and Denali to Collaborate on LRRK2 Program for Parkinson’s Disease and Certain TV Platform-Enabled Programs for Neurodegenerative Diseases
Feb 28, 2019 06:24AM Denali Therapeutics (DNLI) and AbCellera Report Expanded Multi-Year, Multi-Target Deal to Discover Therapeutic Antibodies for Neurological Diseases
Feb 28, 2019 06:08AM AbCellera and Denali Therapeutics Sign Expanded Multi-Year, Multi-Target Deal to Discover Therapeutic Antibodies for Neurological Diseases
May 30, 2018 04:15PM F-star Announces Early Exercise by Denali Therapeutics of its Option to Acquire F-star Gamma
Dec 8, 2017 06:00AM Denali Therapeutics Inc. (Nasdaq: DNLI) to Ring The Nasdaq Stock Market Opening Bell in Celebration of Its IPO